Samsca®_Pharmaceuticals_Otsuka (China) Investment Co., Ltd.


  Tolvaptan is the world's first oral, high selective V2-receptor antagonist. Tolvaptan is indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia [serum sodium < 125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction], including patients with heart failure, cirrhosis, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH).

Product link:

   Zhejiang Otsuka Pharmaceutical Co.,Ltd. >>

Site Map | Legal Statement  | Contact Us

Copyright (c) 2016 Otsuka(China) Investment Co., Ltd. © 2016| 备案号:沪ICP备14028746号